Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer

Oestrogen receptor-binding fragment associated gene 9, EBAG9, is an oestrogen-responsive gene that was identified in MCF-7 human breast carcinoma cell line. It is identical to RCAS 1, a cancer cell surface antigen possibly involved in immune escape. In the present study, we examined the expression of EBAG9/RCAS1 in human epithelial ovarian cancer using immunohistochemistry, immunoblotting and reverse transcription–polymerase chain reaction (RT–PCR). A total of 90 epithelial ovarian cancer cases were examined immunohistochemically by means of the antibodies for EBAG9 and ERα. The correlation between EBAG9 immunoreactivity and clinicopathological parameters was examined. mRNA expression of EBAG9 and ERα were evaluated by RT–PCR in 22 cases. The expression for EBAG9 and ERα was examined by immunoblotting in 12 ovarian cancer cell lines. EBAG9 immunoreactivity was detected in the surface and cytoplasm of carcinoma cells in 46 out of 90 cases (51.1%). EBAG9 expression was significantly higher in serous histology (P=0.0402) and advanced disease (P=0.0206). No significant relationship was detected between EBAG9 immunoreactivity and overall survival (P=0.689). There was a highly significant correlation between EBAG9 and ER immunoreactivity (P<0.0001). The EBAG9 mRNA was detected in 20 out of 22 cases. In all of the cases that were positive for ERα mRNA, they were also positive for EBAG9 mRNA. Immunoreactive band corresponding to EBAG9 was detected in 11 out of 12 of ovarian cancer cell lines, and was consistent with ERα expression. In conclusion, the wide distribution of EBAG9 and its relation to advanced disease suggest that this protein may play important roles in epithelial ovarian cancer.

[1]  F. Landoni,et al.  Steroid receptors in epithelial ovarian carcinoma: relation to clinical parameters and survival. , 1988, Cancer research.

[2]  W. McGuire.  Steroid receptors in human breast cancer. , 1978, Cancer research.

[3]  H Nagura,et al.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.

[4]  A. Miyauchi,et al.  Overexpression of Human Tumor-Associated Antigen, RCAS1, Is Significantly Linked to Dedifferentiation of Thyroid Carcinoma , 2002, Oncology.

[5]  T. Oshikiri,et al.  The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. , 2002, Cancer letters.

[6]  S. Inoue,et al.  Promoter analysis and chromosomal mapping of human EBAG9 gene. , 2000, Biochemical and biophysical research communications.

[7]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma , 1998, Cancer.

[8]  Y. Nakanishi,et al.  Expression of tumor‐associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma , 2001, Cancer.

[9]  M. di Paola,et al.  Histology of bronchial carcinoma and regional lymph nodes as putative immune response of the host to the tumor. , 1977, The Journal of thoracic and cardiovascular surgery.

[10]  T. Kaku,et al.  Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasias. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  B. Slotman,et al.  Endocrine factors in common epithelial ovarian cancer. , 1991, Endocrine reviews.

[12]  Takashi Suzuki,et al.  Expression of 5α‐Reductases in Human Epithelial Ovarian Cancer: Its Correlation with Androgen Receptor Status , 2001, Japanese journal of cancer research : Gann.

[13]  M. Nakashima,et al.  Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1 , 1999, Nature Medicine.

[14]  T. Oshikiri,et al.  High expression of tumor‐associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker , 2002, International journal of cancer.

[15]  S. Inoue,et al.  Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. , 2001, Biochemical and biophysical research communications.

[16]  T. Benraad,et al.  Do Estrogen and Progesterone Receptors (E2R and PR) in Metastasizing Endometrial Cancers Predict the Response to Gestagen Therapy? , 1980, Acta obstetricia et gynecologica Scandinavica.

[17]  F. Akiyama,et al.  Toward the development of a universal grading system for ovarian epithelial carcinoma. I. Prognostic significance of histopathologic features--problems involved in the architectural grading system. , 1998, Gynecologic oncology.

[18]  K. Shiromizu,et al.  Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. , 2001, Gynecologic oncology.

[19]  Takashi Suzuki,et al.  Differential Expression of Progesterone Receptor Isoforms A and B in the Normal Ovary, and in Benign, Borderline, and Malignant Ovarian Tumors , 2002, Japanese journal of cancer research : Gann.

[20]  T. Kaku,et al.  A novel tumor‐associated antigen expressed in human uterine and ovarian carcinomas , 1996, Cancer.

[21]  Y. Nakamura,et al.  Overrepresentation of the EBAG9 gene at 8q23 associated with early-stage breast cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  J. Lakins,et al.  Expression and regulation of estrogen receptor beta in human breast tumors and cell lines. , 2000, Oncology reports.

[23]  M. Piver,et al.  Progesterone receptor status is a significant prognostic variable of progression-free survival in advanced epithelial ovarian cancer. , 1998, American journal of clinical oncology.

[24]  M. Schemper,et al.  Oestrogen and progesterone receptor content as a prognostic factor in advanced epithelial ovarian carcinoma , 1990, British journal of obstetrics and gynaecology.

[25]  N. Harada,et al.  Aromatase and 17 beta-hydroxysteroid dehydrogenase type 1 in human breast carcinoma. , 1996, The Journal of clinical endocrinology and metabolism.

[26]  S. Rosenberg,et al.  The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens. , 1996, Annual review of medicine.

[27]  S. Masood,et al.  Clinical correlation of hormone receptor status in epithelial ovarian cancer. , 1989, Gynecologic oncology.

[28]  S. Inoue,et al.  Isolation of Estrogen-Responsive Genes with a CpG Island Library , 1998, Molecular and Cellular Biology.

[29]  A. Kauppila.  Progestin Therapy of Endometrial, Breast and Ovarian Carcinoma , 1984, Acta obstetricia et gynecologica Scandinavica.

[30]  C. Balch,et al.  Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. , 1990, Archives of surgery.

[31]  S. Inoue,et al.  EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine–immune interactions , 2001, British Journal of Cancer.

[32]  R. Cleary,et al.  Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications. , 1981, American journal of obstetrics and gynecology.

[33]  T. Kaku,et al.  The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. , 2000, Gynecologic oncology.

[34]  D. Fortune,et al.  Cytoplasmic steroid receptors in ovarian tumours , 1982, British journal of obstetrics and gynaecology.

[35]  T. Kaku,et al.  The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.